[Treatment strategy to obtain cure for recurrent advanced breast cancer].
The three-year survival rate of a total of 186 patients with recurrent advanced breast cancer was 86% for complete responders, 27% for partial responders, and 29% for patients remaining in stable diseases, respectively, at our two institutions. Thus, the results indicated that a complete response is the first step for long-term survival. High-dose chemotherapy with autologous stem cell support was administered after 4 cycles of induction chemotherapy. The results showed 12 complete response (60%) out of 20 patients, and 5 cases survived with no evidences of disease for 5-31 months. Both taxol and taxotere achieved response rates exceeding 50% in phase II trials on advanced breast cancer and therefore were expected to have a role in combination regimens with other drugs.
Ogawa
M
M
Aichi Cancer Center, Tokai University School of Medicine.
Mukaiyama
T
T
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000628:therapy*; D016190:Carboplatin / Q000008:administration & dosage; D002330:Carmustine / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000008:administration & dosage; D004334:Drug Administration Schedule; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D013852:Thiotepa / Q000008:administration & dosage
D016179:Granulocyte Colony-Stimulating Factor; D015251:Epirubicin; D005047:Etoposide; D003520:Cyclophosphamide; D013852:Thiotepa; D016190:Carboplatin; D002330:Carmustine